Axa’s Madrigal Pharmaceuticals MDGL Stock Holding History

Axa’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,300	Closed	-$377K	–	1151
2022 Q4	$377K	Buy	+1,300	New	+$127K	﹤0.01%	1021
2019 Q1	–	Sell	-4,600	Closed	-$519K	–	1355
2018 Q4	$519K	Sell	4,600 -1,700	-27%	-$263K	﹤0.01%	1081
2018 Q3	$1.35M	Hold	6,300	–	–	﹤0.01%	967
2018 Q2	$1.76M	Buy	+6,300	New	+$1.11M	0.01%	888

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Axa's MDGL Position: Q1 2023 in Review

Axa sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2023, closing a stake of 1,300 shares — an estimated $377K sold.

Axa first reported a position in MDGL in Q2 2018 and held it in 4 quarters. The position peaked at $1.76M in Q2 2018. 223 funds tracked by Wall St. Rank hold MDGL as of Q1 2023.

Axa reported no remaining Madrigal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Axa sold 1,300 Madrigal Pharmaceuticals shares in Q1 2023, an estimated $377K.
Axa first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
Axa's Madrigal Pharmaceuticals position peaked at $1.76M in Q2 2018.
223 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.